Lilly Eyes Quick FDA Approval For Orforglipron In Obesity, While Novo Submits CagriSema

Phase III Data Support Oral Drug As Maintenance

 
• By Joseph Haas
  
Lilly expects quick turnaround on its FDA filing of orforglipron • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business